Luminex cytokine assays are common bead-based multiplex ELISA assays conducted in 96-well plate formats in 100 µL volume ranges. The theoretical principle of Luminex cytokine assays are based on ...

Luminex Corporation will unveil FlexMAP 3D™, its next generation bead-based multiplexing system, today at the American Association for Clinical Chemistry (AACC) Annual Meeting in San Diego. FlexMAP 3D ...

We currently support a Luminex 200 (and Bio-Plex 200) instrument and have optimized and provided Luminex assays for cytokines, growth factors, apoptosis, cancer, metabolic markers and Akt and MAP ...

Luminex is gaining $1.21, or 30 percent, to $5.25, after the company agreed to license its biological testing technologies to Abbott Labs . The deal covers Luminex's bead-based xMAPtechnology ...

Rapidly evolving genomic technologies have spawned the Tm/Luminex Universal Array Platform, capable of reading 10,000 single nucleotide polymorphisms (SNPs) per hour. Distributed by Luminex of Austin, ...

“Adopting Luminex’s bead-based xMAP® technology dramatically increased the power and scope of our food allergy diagnostic,” said Jim Garner, CEO and board member of AllerGenis. “We have ...

The beads were washed and incubated with biotinylated Humira to detect drug specific ADA captured on each bead set. Streptavidin-phycoerythrin was added followed by analysis of the bead sets in a ...

We currently support a Luminex 200 (and Bio-Plex 200) instrument and have optimized and provided Luminex assays for cytokines, growth factors, apoptosis, cancer, metabolic markers and Akt and MAP ...